New drug duo targets hard-to-treat bile duct cancer
NCT ID NCT05874414
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, GNS561 and trametinib, in people with advanced bile duct cancer that has a specific genetic change (KRAS mutation) and has not responded to standard first-line therapy. The trial has two phases: first to find the safest dose, then to see if the combination shrinks tumors. About 74 adults will take part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GNS561 (ezurpimtrostat) and trametinib
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced bile duct cancer that has a KRAS mutation and has stopped responding to standard chemotherapy.
What could go wrong
This is an early-phase trial with only 74 participants, so the drug combination may not prove effective or safe enough for wider use. Side effects could be serious, and the cancer may still progress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert Hospital and the Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact
-
Hospital of the University of Pennsylvania
TERMINATEDPhiladelphia, Pennsylvania, 19104, United States
-
LACN Aneheim Flagship Office
RECRUITINGLos Angeles, California, 92805, United States
Contact
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
-
Orlando Health
RECRUITINGOrlando, Florida, 32806, United States
Contact
-
Pan American Center for Oncology Trials, LLC
RECRUITINGRio Piedras, Puerto Rico, 00935, Puerto Rico
Contact
-
Roswell Park Cancer Institute
TERMINATEDBuffalo, New York, 14263, United States
-
USC Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
Contact
-
University Of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
Contact
-
University of Texas, MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
University of Virginia Comprehensive Cancer Center
RECRUITINGCharlottesville, Virginia, 22908, United States
Contact